<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title>Our Projects and Publications</title>

<script src="site_libs/header-attrs-2.16/header-attrs.js"></script>
<script src="site_libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/journal.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="site_libs/jqueryui-1.11.4/jquery-ui.min.js"></script>
<link href="site_libs/tocify-1.9.1/jquery.tocify.css" rel="stylesheet" />
<script src="site_libs/tocify-1.9.1/jquery.tocify.js"></script>
<script src="site_libs/navigation-1.1/tabsets.js"></script>
<script src="site_libs/navigation-1.1/codefolding.js"></script>
<link href="site_libs/highlightjs-9.12.0/default.css" rel="stylesheet" />
<script src="site_libs/highlightjs-9.12.0/highlight.js"></script>
<link href="site_libs/font-awesome-5.1.0/css/all.css" rel="stylesheet" />
<link href="site_libs/font-awesome-5.1.0/css/v4-shims.css" rel="stylesheet" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>






<link rel="stylesheet" href="style2.css" type="text/css" />



<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "&#xe258;";
  border: none;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->
<style type="text/css">
.code-folding-btn { margin-bottom: 4px; }
</style>



<style type="text/css">

#TOC {
  margin: 25px 0px 20px 0px;
}
@media (max-width: 768px) {
#TOC {
  position: relative;
  width: 100%;
}
}

@media print {
.toc-content {
  /* see https://github.com/w3c/csswg-drafts/issues/4434 */
  float: right;
}
}

.toc-content {
  padding-left: 30px;
  padding-right: 40px;
}

div.main-container {
  max-width: 1200px;
}

div.tocify {
  width: 20%;
  max-width: 260px;
  max-height: 85%;
}

@media (min-width: 768px) and (max-width: 991px) {
  div.tocify {
    width: 25%;
  }
}

@media (max-width: 767px) {
  div.tocify {
    width: 100%;
    max-width: none;
  }
}

.tocify ul, .tocify li {
  line-height: 20px;
}

.tocify-subheader .tocify-item {
  font-size: 0.90em;
}

.tocify .list-group-item {
  border-radius: 0px;
}


</style>



</head>

<body>


<div class="container-fluid main-container">


<!-- setup 3col/9col grid for toc_float and main content  -->
<div class="row">
<div class="col-xs-12 col-sm-4 col-md-3">
<div id="TOC" class="tocify">
</div>
</div>

<div class="toc-content col-xs-12 col-sm-8 col-md-9">




<div class="navbar navbar-default  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">Ferrari Lab at Columbia University</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="about.html">About Us</a>
</li>
<li>
  <a href="projects.html">Projects and Publications</a>
</li>
<li>
  <a href="biobank.html">Biobank</a>
</li>
<li>
  <a href="program.html">Research Program for Residents</a>
</li>
<li>
  <a href="https://columbiasurgery.org/heart/">
    <span class="fa fa-user-md fa-lg"></span>
     
  </a>
</li>
<li>
  <a href="mailto:&lt;gf2375@cumc.columbia.edu&gt;">
    <span class="fa fa-telegram fa-lg"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">

<div class="btn-group pull-right float-right">
<button type="button" class="btn btn-default btn-xs btn-secondary btn-sm dropdown-toggle" data-toggle="dropdown" data-bs-toggle="dropdown" aria-haspopup="true" aria-expanded="false"><span>Code</span> <span class="caret"></span></button>
<ul class="dropdown-menu dropdown-menu-right" style="min-width: 50px;">
<li><a id="rmd-show-all-code" href="#">Show All Code</a></li>
<li><a id="rmd-hide-all-code" href="#">Hide All Code</a></li>
</ul>
</div>



<h1 class="title toc-ignore">Our Projects and Publications</h1>
<h3 class="subtitle"><em>Columbia University Irving Medical Center
Cardiothoracic Surgery Research Program</em></h3>

</div>


<head>
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/4.7.0/css/font-awesome.min.css">
</head>
<p><br />
</p>
<div id="mitral-valve" class="section level1">
<h1><a id="Mitral"></a>Mitral Valve<br />
</h1>
<div id="myxomatous-mitral-valve-disease" class="section level2">
<h2>Myxomatous Mitral Valve Disease</h2>
<p>Degenerative mitral regurgitation (MR) due to myxomatous valve
disease affects millions. The only treatment is either valve repair or
replacement. This project will advance understanding of the role of the
neurotransmitter, serotonin (5HT) in MR. Heart valve disease has been
associated with both 5HT-secreting carcinoid tumors and medications,
such as the diet drug, Dexfenfluoramine. We will investigate the
hypothesis that 5HT-mechanisms involving the serotonin transporter
(SERT), and 5HT receptor (HTR) signaling, both in platelets and mitral
valve interstitial cells (MVIC) of bone marrow origin, contribute to the
pathophysiology MR, and represent promising therapeutic targets. It is
expected that the mechanistic results of these studies will lead to
therapeutic directions for MR that target platelet-derived 5HT and
leverage a personalized approach using BOEC to model the
pathophysiology.</p>
<br />

<center>
<p><img src="images/mitral.jpg" style="width:75.0%" /></p>
<p><br />
</p>
</center>
<br />

<body>
<p><em>Funding Source</em><br />
<em>NIH R01HL131872 (Ferrari G - Levy RJ)</em><br />
<i class='fas fa-flask'></i> <a
href="https://reporter.nih.gov/search/ZaoPhLvNK0GqfjFCGu3xvw/project-details/10130913">NIH
Reporter</a></p>
<p><br />
</p>
</div>
<div id="ischemic-mitral-regurgitation" class="section level2">
<h2>Ischemic Mitral Regurgitation<br />
</h2>
<p>Ischemic mitral regurgitation (IMR) often develops after an ischemic
event, which results in distortion of the valvulo-ventricular complex
and incomplete mitral valve (MV) leaflet coaptation. After left
ventricular ischemic events, only some patients develop IMR. The
susceptibility of the MV to remodel may influence whether IMR develops.
We hypothesized that impaired signaling response in MV cells may
contribute to IMR development by inducing maladaptive tissue
remodeling.</p>
<br />

<center>
<p><img src="images/Ischemic%20MR.jpg" style="width:75.0%" /></p>
<p><br />
</p>
</center>
<p><br />
</p>
<hr />
<p><br />
</p>
</div>
</div>
<div id="aortic-valve" class="section level1">
<h1><a id="AV"></a>Aortic Valve<br />
</h1>
<div id="calcific-aortic-valve-disease" class="section level2">
<h2>Calcific Aortic Valve Disease<br />
</h2>
<p>This program is concerned with modulating oxidative glycation
reactions in specimens from patients with variable degrees of Calcific
Aortic Valve Disease (CAVD), a disease which, despite decades of
investigation, remains without effective medical therapy. CAVD defines a
spectrum of disorders from initial asymptomatic remodeling (aortic valve
sclerosis; AVSc) to outflow obstruction (Aortic Stenosis, AS) that
result in heart failure and death if not treated surgically. Over 30% of
patients over 65 years of age have some degree AVSc and close to 10% of
those develop severe symptomatic AS within a decade from diagnosis. Once
AVSc is detected, there is an increased risk of adverse cardiovascular
events. At the onset of mild symptoms (early AS), survival is further
reduced, with a dramatic decline in patients with severe symptomatic AS.
Thus, understanding the development of AVSc and its progression into AS
is of high clinical significance for a very large cohort of patients.
CAVD defines a spectrum of diseases from initial structural remodeling
to outflow obstruction that could result in heart failure, and death. We
discovered that glyco-oxidation moieties impact the AV via two
pathological mechanisms: First, they modify the ECM via cross-linking of
collagen/elastin and permanent incorporation of glycated circulating
proteins. Second, they activate VICs towards the osteogenic phenotype:
AGE binds RAGE which, via NADPH, generates ROS. AGEs and ROS mediate the
DNA damage response that controls VIC phenotype. Both mechanisms lead to
stiffening, mass increase, and calcification.</p>
<br />

<center>
<p><img src="images/Revised%20AS%20Figure_grant%20copy.png"
style="width:75.0%" /></p>
<p><br />
</p>
</center>
<p><br />
</p>
<hr />
<p><br />
</p>
</div>
</div>
<div id="aorta" class="section level1">
<h1><a id="Aorta"></a>Aorta<br />
</h1>
<div id="aortic-aneurysm-and-dissection" class="section level2">
<h2>Aortic Aneurysm and Dissection<br />
</h2>
<p>Bicuspid Aortic Valve (BAV) syndrome is associated with frequent and
premature occurrence of calcific aortic stenosis (AS) and thoracic
aortic aneurysms (TAA), with 30-50% of BAV patients requiring surgery in
their lifetime for AS, TAA, or both. It is estimated that 1.4% of the
population is born with a BAV, making it the most common congenital
heart defect in the US. Eccentric flow dynamics, endothelial
dysfunction, and genetic predisposition are key elements impacting the
susceptibility of BAV patients to adverse aortic events. Dissection and
rupture are mechanical failures of the aortic wall that occurs when the
tensile limit of the aortic tissue is overwhelmed. To prevent these
events, the ascending aorta is preventively replaced in high-risk
patients. The major clinical obstacles hampering the decisions of
whether replace the ascending aorta of BAV patients are the absence, in
the current guidelines, of any tools informing on the structural
integrity of the aortic wall independently of metric measurements and of
any non-invasive risk-assessment tools. Here we tested the mechanistic
hypothesis that mitigation of glycoxidation reactions revert
AGE-mediated paracellular endothelial hyperpermeability and reduce the
accumulation of glycooxidation products in the ascending aorta of BAV
patients.</p>
<br />

<center>
<p><img src="images/Aneurysm.png" style="width:75.0%" /></p>
<p><br />
</p>
</center>
<p><br />
</p>
<p><em>Funding Source</em><br />
<em>R01 HL122805</em><br />
<i class='fas fa-flask'></i> <a
href="https://reporter.nih.gov/search/ZaoPhLvNK0GqfjFCGu3xvw/project-details/9762185">NIH
Reporter</a></p>
<p><br />
</p>
<hr />
<p><br />
</p>
</div>
</div>
<div id="biomedical-engineering" class="section level1">
<h1><a id="BME"></a>Biomedical Engineering</h1>
<div
id="glycation-mediated-mechanisms-of-bioprosthetic-heart-valve-failure"
class="section level2">
<h2>Glycation-mediated Mechanisms of Bioprosthetic Heart Valve
Failure<br />
</h2>
<p>Heart valve disease at this time can only be treated surgically, with
either valve replacement or repair. Bioprosthetic heart valves (BHV),
fabricated from glutaraldehyde fixed heterografts, such as bovine
pericardium (BP) or porcine aortic valves (PAV), are widely used in both
cardiac surgery and in transcatheter valve replacements. Despite
outstanding short-term outcomes, BHV dysfunction due to structural valve
leaflet degeneration (SVD) develops over time, frequently necessitating
device replacement. Calcification is observed in the majority of SVD
cases; however, 25% or more SVD cases are not associated with
calcification. Recent work from our group demonstrated that BHV are
susceptible to non-calcification induced failure mechanisms, involving
the formation of unique oxidized amino acids (OxAA) in BHV, such as the
crosslink, di-tyrosine (di-Tyr). Feasibility studies also recently
documented in BHV explant samples the presence of advanced glycation end
products (AGE). The contributions of both AGE and OxAA to SVD
pathophysiology has not been previously investigated by our group or
others. We are studying the hypotheses that the accumulation of AGE in
BHV leaflets together with the receptor for AGE (RAGE) mediated
inflammatory response, and OxAA modification of structural proteins
contribute to BHV SVD. These mechanisms also are hypothesized to
interact with BHV calcification and co-morbidities, such as diabetes and
coronary artery disease to enhance SVD.</p>
<br />

<center>
<p><img src="images/Bioprosthetic%20R01.png" style="width:75.0%" /></p>
<p><br />
</p>
</center>
<p><br />
</p>
<p><em>Funding Source</em><br />
<em>R01HL143008</em><br />
<i class='fas fa-flask'></i> <a
href="https://reporter.nih.gov/search/EpM1RwPYiUeXjqUjLqrCFg/project-details/10202704">NIH
Reporter</a></p>
<p><br />
</p>
</div>
<div
id="structural-degeneration-of-implantable-biomaterials-in-pediatric-patients"
class="section level2">
<h2>Structural Degeneration of Implantable Biomaterials in Pediatric
Patients<br />
</h2>
<p>Despite legislation and federal initiatives, such as the Pediatric
Device Consortia Grants Program, intended to facilitate pediatric
medical device development, innovation for pediatric cardiac patients
continues to lag behind the advances made for adult devices, making
children requiring reconstructive heart surgery an underserved
population. All implantable biomaterials (glutaraldehyde bovine
pericardium, xenograft valves and conduits, cryopreserved allografts,
autologous pericardium, and collagen bioscaffolds) as well as some
artificial polymers are subjected to structural degeneration driven by
calcification (via passive calcium deposition and absorption of
calcium-binding proteins) and – as discovered by our group – by
glyco-oxidation, which via permanent incorporation of glycated protein
and cross-links formation, alters the architecture and mechanical
proprieties of biomaterials.</p>
<p>This application has two overarching goals: to understand the
mechanisms of accelerate structural degeneration of cardiac patches,
valved conduits, and bioprosthetic heart valves in children and to test
mitigation strategies to extend the lifespan of these devices in vitro
and in vivo by using juvenile animal models. Clinically, the goal is to
reduce the need for multiple cardiac re-operations in pediatric patients
by mitigating the mechanisms at the base of the accelerated failure.</p>
<br />

<center>
<p><img src="images/Pediatric%20BHV.png" style="width:75.0%" /></p>
<p><br />
</p>
</center>
<p><br />
</p>
</div>
<div
id="sexual-dimorphism-and-durability-of-implanted-biomaterials-in-patients-with-type-2-diabetes-mellitus"
class="section level2">
<h2>Sexual Dimorphism and Durability of Implanted Biomaterials in
Patients with Type 2 Diabetes Mellitus<br />
</h2>
<p>Type 2 Diabetes mellitus (T2DM) is a well-known risk factor for heart
valve disease, little is known about the mechanisms of accelerated
failure of Bioprosthetic Heart Valve in this population. Using a
next-generation proteomic approach on an established biobank of
retrieved failed Bioprosthetic Heart Valve (BHV) explants and a patented
precision medicine susceptibility assay using patient-derived serum we
will assess how sexual dimorphism impact the durability of bioprosthetic
heart valves in T2DM patients. Mitigation strategies aimed at reducing
glycoxidation reactions will be tested to clinically graded valves
chemically modified to improve the Bioprosthetic Valve durability of
T2DM patients.</p>
<br />

<center>
<p><img src="images/T2DM.png" style="width:75.0%" /></p>
<p><br />
</p>
</center>
<p><br />
</p>
<p><em>Funding Source</em><br />
<em>Russell Berrie Foundation Pre-translational Diabetes Research
Award</em><br />
<i class='fas fa-vial'></i> <a
href="https://www.russellberriefoundation.org/diabetes-care-and-research"><em>Russell
Berrie Foundation</em></a></p>
<p><br />
</p>
<hr />
<p><br />
</p>
</div>
</div>
<div id="covid-19-cardiac-injury" class="section level1">
<h1><a id="Covid19"></a>Covid-19 Cardiac Injury</h1>
<div id="mechanisms-of-cardiac-remodeling-in-covid-19-patients"
class="section level2">
<h2>Mechanisms of Cardiac Remodeling in COVID-19 Patients</h2>
<p>As a result of the COVID-19 pandemic, it has been shown that patients
with pre-existing heart disease are likely to have more severe COVID-19
symptoms than those without pre-existing heart disease. We seek to test
the hypothesis that SARS-CoV-2 induces cardiac injury by decreasing
ACE2-mediated cardioprotection, and exacerbating AGE/RAGE-mediated cell
signaling mechanisms. The 2 major things we seek to address are if this
cell signaling pathway induces cardiac injury, and if circulating RAGE
signaling markers be used as biomarkers of cardiovascular injury during
acute COVID infection, and after recovery from infection.</p>
<br />

<center>
<p><img src="images/COVID.png" style="width:75.0%" /></p>
<p><br />
</p>
</center>
<p><br />
</p>
<p><em>Funding Source</em><br />
<em>John Jones Surgical Society Fellowship</em><br />
<i class='fas fa-book'></i> <a
href="https://columbiasurgery.org/alumni/john-jones-surgical-society"><em>John
Jones Surgical Society</em></a></p>
<p><br />
</p>
<hr />
<p><br />
</p>
</div>
</div>
<div id="surgical-innovation" class="section level1">
<h1><a id="Innovation"></a>Surgical Innovation<br />
</h1>
<p><br />
</p>
<div id="ageless-valve" class="section level2">
<h2>AGEless Valve</h2>
<p><br />
</p>
<div
id="anti-glycation-modification-of-bioprosthetic-heart-valve-tissues-to-enhance-valve-lifespan"
class="section level3">
<h3>Anti-Glycation Modification of Bioprosthetic Heart Valve Tissues to
Enhance Valve Lifespan<br />
</h3>
<p><a href="http://columbiabiomedx.com/ageless">AGEless Valve
Website</a><br />
</p>
<p><br />
</p>
<div id="unmet-medical-need" class="section level4">
<h4>Unmet Medical Need<br />
</h4>
<p>A way to address Bioprosthetic heart valves (BHV) glycation in heart
valve replacement patients in order to mitigate structural valve
degeneration and device failure</p>
</div>
<div id="envisioned-healthcare-product" class="section level4">
<h4>Envisioned Healthcare Product<br />
</h4>
<p>The technology aims to extend BHV lifespans by chemically modifying
BHV tissues to render them inert to physiologic glycation and associated
protein incorporation, two interacting, key mechanisms of SVD they
recently discovered. By addressing BHV glycation in heart valve
replacements, the team hopes to mitigate structural valve degeneration
and device failure for all BHV implant recipients, especially younger
patients and diabetics.</p>
<p><br />
</p>
<p><br />
</p>
<p><br />
</p>
<p><br />
</p>
</body>
 
<hr />
<p style="text-align: center;">
Created by Alexey Abramov MD</a>
</p>
<p style="text-align: center;">
<span style="color: #808080;"><em><a
href="mailto:aa3832@cumc.columbia.edu"
class="email">aa3832@cumc.columbia.edu</a></em></span>
</p>
<!-- Add font awesome icons -->
<p style="text-align: center;">
<a href="https://twitter.com/aabramov_md?lang=en" class="fa fa-twitter"></a>
<a href="https://www.linkedin.com/in/abramovmd/" class="fa fa-linkedin"></a>
<a href="https://github.com/aabramov90/" class="fa fa-github"></a>
<p style="text-align: center;">
© Copyright 2021, Ferrari Lab at Columbia University</a>
</p>
<p> </p>
</div>
</div>
</div>
</div>



</div>
</div>

</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->
<script>
$(document).ready(function () {
  window.initializeCodeFolding("hide" === "show");
});
</script>

<script>
$(document).ready(function ()  {

    // temporarily add toc-ignore selector to headers for the consistency with Pandoc
    $('.unlisted.unnumbered').addClass('toc-ignore')

    // move toc-ignore selectors from section div to header
    $('div.section.toc-ignore')
        .removeClass('toc-ignore')
        .children('h1,h2,h3,h4,h5').addClass('toc-ignore');

    // establish options
    var options = {
      selectors: "h1,h2,h3",
      theme: "bootstrap3",
      context: '.toc-content',
      hashGenerator: function (text) {
        return text.replace(/[.\\/?&!#<>]/g, '').replace(/\s/g, '_');
      },
      ignoreSelector: ".toc-ignore",
      scrollTo: 0
    };
    options.showAndHide = true;
    options.smoothScroll = true;

    // tocify
    var toc = $("#TOC").tocify(options).data("toc-tocify");
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
